

A Phase Ib study of xentuzumab plus abemaciclib and fulvestrant in patients with advanced HR+, HER2-negative breast cancer with visceral or non-visceral disease

#1057

Douglas Yee,^{1*} Patricia LoRusso,² Marie Paule Sablin,³ Aleix Prat,⁴ Agostina Stradella,⁵ Meri Utriainen,⁶ Mafalda Oliveira,⁷ Kan Yonemori,⁸ Yoichi Naito,⁹ Molly Catherine Hardebeck,¹⁰ Marta Puig,¹¹ Joy Hu,¹² Tsvetan Biyukov,¹³ Hiroji Iwata¹⁴

¹Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA; ²Yale Cancer Center, Yale University, New Haven, CT, USA; ³Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France; ⁴Hospital Clinic of Barcelona, Barcelona, Spain; ⁵Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain; ⁶Helsinki University Central Hospital, Comprehensive Cancer Center and University of Helsinki, Helsinki, Finland; ⁷Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain; ⁸National Cancer Center Hospital, Tokyo, Japan; ⁹National Cancer Center Hospital East, Kashiwa, Japan; ¹⁰Global Oncology Development, Eli Lilly and Company, Indianapolis, IN, USA; ¹¹Boehringer Ingelheim España S.A., Barcelona, Spain; ¹²Boehringer Ingelheim (People's Republic of China) Investment Co., Ltd., Shanghai, China; ¹³Boehringer Ingelheim International GmbH, Ingelheim, Germany; ¹⁴Aichi Cancer Center Hospital, Nagoya, Japan

Introduction

- CDK4 & 6 inhibitors, such as abemaciclib, in combination with ET are standard of care for advanced HR+ BC¹
- Activation of the IGF-1R results in increased cyclin D1 expression,² providing a rationale for combining IGF and CDK4 & 6 inhibition
- Xentuzumab is an IGF ligand-neutralizing antibody.³ Xentuzumab plus exemestane and everolimus has shown PFS benefit in a subgroup of patients with advanced HR+ BC and non-visceral disease⁴

Objectives

- NCT03099174 is a prospective, open-label study investigating xentuzumab + abemaciclib ± ET. In dose-finding cohorts, the RP2D was determined as xentuzumab 1000 mg weekly + abemaciclib 150 mg Q12h ± ET⁵
- We present interim secondary endpoint data from expansion cohorts in patients with advanced HR+ BC and visceral or non-visceral disease

Methods

Further details available via QR code

Expansion cohorts in patients with advanced HR+/HER2- breast cancer Xentuzumab 1000 mg i.v. weekly + abemaciclib 150 mg p.o. Q12h + fulvestrant 500 mg per label	
Cohort D1	Cohort D2
≥1 documented visceral metastasis*	No visceral metastases
Progression on or after ET (including adjuvant ET)	
No prior CDK4 & 6 inhibitor therapy	
No more than one line of prior endocrine-based therapy or any CT for advanced or metastatic disease	

Primary endpoint: PFS rate at 18 months (*data currently immature*)

Secondary endpoints: DCR (CR, PR or SD ≥ Week 24), OR (CR or PR), time to OR, duration of OR and DCR, PFS

*Includes lung, liver, pleural and peritoneal metastases, malignant pleural effusion and malignant peritoneal effusion involvement

Patients and treatment

- 33/31 patients were treated in Cohorts D1/D2, respectively; at data cut-off (31 Mar 2021*), 14/21 remain on treatment
- 19 patients had discontinued treatment in D1 (14 due to PD) and 10 had discontinued in D2 (6 due to PD)
- In Cohort D2, 20 patients had bone-only, non-measurable disease; other characteristics are shown below

	D1 (N=33)	D2 (N=31)
Female, n (%)	33 (100)	31 (100)
Median age, years (range)	60.0 (36–78)	53.0 (36–80)
Menopausal status (pre/peri/post), n (%)†	2 (6.1) / 4 (12.1) / 27 (81.8)	9 (29.0) / 2 (6.5) / 20 (64.5)
Median time since first metastasis/recurrence, months (range)	1.9 (0.1–208.8)	2.1 (0.7–90.5)
Prior adjuvant CT, n (%)	23 (69.7)	24 (77.4)
Prior ET, n (%)	32 (97.0)	27 (87.1)

*Updated versus abstract; †all pre/perimenopausal patients had chemical/surgical/radiation-induced postmenopausal status.

AE, adverse event; BC, breast cancer; CDK, cyclin-dependent kinase; CR, complete response; CT, chemotherapy; DCR, disease control rate; ET, endocrine therapy; HER2-, human epidermal growth factor receptor 2 negative; HR+, hormone receptor-positive; IGF, insulin-like growth factor; IGF-1R, IGF 1 receptor; i.v., intravenously; OR, overall response; PD, progressive disease; PFS, progression-free survival; p.o., orally; PR, partial response; Q12h, every 12 hours; RP2D, recommended phase 2 dose; SD, stable disease

Key findings and conclusions

- Xentuzumab plus abemaciclib and fulvestrant demonstrated encouraging disease control in patients with advanced HR+ BC with visceral and non-visceral disease
- DCR was 66.7% in patients with visceral metastases and 74.2% in those without



- The safety profile was manageable and consistent with the known profiles of the three agents
- The triplet combination will be further evaluated in patients with advanced HR+ BC without visceral metastases that has progressed on aromatase inhibitor and CDK4 & 6 inhibitor therapy (excluding abemaciclib; currently recruiting ~20 patients)

Copies of this poster obtained through Quick Response (QR) Code are for personal use only and may not be reproduced without permission from ASCO® and the authors of this poster


*Corresponding author email address: yeex006@umn.edu

Interim efficacy

Further details available via QR code

	D1 (N=33)	D2 (N=31)
DCR, n (%)	22 (66.7)	23 (74.2)
PR	18 (54.5)	5 (16.1)*
Non-CR/non-PD ≥ Week 24	–	15 (48.4)
SD ≥ Week 24	4 (12.1)	3 (9.7)
Median duration of disease control, months (range)	12.2 (7.2–16.6)	12.9 (5.3–19.4)

*In the non-visceral Cohort (D2), 20 patients had non-measurable disease



Safety

Further details available via QR code

Patients with:*	D1 (N=33)		D2 (N=31)	
	All	Grade ≥3	All	Grade ≥3
Any AE	33 (100)	27 (81.8)	31 (100)	27 (87.1)
Diarrhea	29 (87.9)	1 (3.0)	28 (90.3)	4 (12.9)
Nausea	21 (63.6)	0	20 (64.5)	2 (6.5)
Neutrophil count decreased	18 (54.5)	12 (36.4)	15 (48.4)	11 (35.5)
Anemia	13 (39.4)	1 (3.0)	11 (35.5)	1 (3.2)
Asthenia	12 (36.4)	0	9 (29.0)	1 (3.2)
Muscle spasms	12 (36.4)	0	5 (16.1)	0
Platelet count decreased	10 (30.3)	0	13 (41.9)	1 (3.2)
Headache	10 (30.3)	0	12 (38.7)	0
Vomiting	9 (27.3)	0	13 (41.9)	2 (6.5)

*Any-cause AEs with incidence >35% in either cohort shown; there was one grade 5 AE (respiratory syncytial virus infection in Cohort D1)

Patients with AEs leading to:	D1 (N=33)	D2 (N=31)
Dose reduction/discontinuation of xentuzumab	0 / 4 (12.1)	10 (32.3) / 4 (12.9)
Dose reduction/discontinuation of abemaciclib	19 (57.6) / 5 (15.2)	21 (67.7) / 8 (25.8)

- No AEs of hyper/hypoglycemia were reported
- One patient had grade 2 interstitial lung disease/pneumonitis in Cohort D2
- There was one grade 2 infusion-related reaction in Cohort D2

References

1. Cardoso F, et al. Ann Oncol 2020;31:1623–49; 2. Tang L, et al. Int J Clin Exp Pathol 2017;10:11652–58; 3. Friedbichler K, et al. Mol Cancer Ther 2014;13:399–409; 4. Schmid P, et al. Breast Cancer Res 2021;23:8; 5. Yee D, et al. Cancer Res 2019;80 (4 Suppl) P3-11-05

Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, Virtual Format, 4–8 June, 2021

The authors were fully responsible for all content and editorial decisions, were involved at all stages of poster development and have approved the final version. The study was funded by Boehringer Ingelheim, with support from Eli Lilly and Company. Medical writing support for the development of this poster, under the direction of the authors, was provided by Caroline Allinson, of Ashfield MedComms, an Ashfield Health company, and funded by Boehringer Ingelheim.